Vascular Endothelial Growth Factor D

A vascular endothelial growth factor that specifically binds to VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2 and VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-3. In addition to being an angiogenic factor it can act on LYMPHATIC VESSELS to stimulate LYMPHANGIOGENESIS. It is similar in structure to VASCULAR ENDOTHELIAL GROWTH FACTOR C in that they both contain N- and C-terminal extensions that were not found in other VEGF family members.

Also Known As:

Networked: 382 relevant articles (11 outcomes, 54 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Stacker, Steven A: 25 articles (02/2014 - 06/2002)
2.	Achen, Marc G: 25 articles (02/2014 - 06/2002)
3.	Alitalo, Kari: 23 articles (02/2015 - 01/2002)
4.	Ylä-Herttuala, Seppo: 13 articles (01/2014 - 10/2003)
5.	Roufail, Sally: 11 articles (08/2013 - 06/2002)
6.	Karnezis, Tara: 9 articles (08/2013 - 04/2007)
7.	Davydova, Natalia: 6 articles (08/2013 - 04/2007)
8.	Shayan, Ramin: 6 articles (08/2013 - 10/2011)
9.	Baldwin, Megan E: 6 articles (05/2013 - 06/2002)
10.	Paavonen, Karri: 6 articles (03/2013 - 01/2002)

Related Diseases

1.	Neoplasm Metastasis (Metastasis) 06/01/2004 - "These data suggest that targeting VEGF D and flt-4t(Delta773-1081) receptors may be particularly effective in the prevention of lymph node metastases." 02/01/2003 - "The purpose of this study is to determine whether VEGF-D correlates with lymph node metastasis or prognosis. " 01/01/2015 - "VEGF-D is a potential predictive marker of positive lymph node metastasis in cN0 patients." 01/01/2015 - "In cases with lymph node metastasis, the VEGF-D-expression score was significantly higher than in those without lymph node metastasis (p = 0.0006). " 01/01/2015 - "High VEGF-D and low MMP-2 serum levels predict LN metastasis in patients with UCB at the time of RC. "
2.	Neoplasms (Cancer) 03/01/2012 - "The definition of the structure of the complex of VEGF-D bound to its receptors would be beneficial for design of inhibitors of VEGF-D signaling aimed at restricting the growth and spread of cancer. " 04/30/2009 - "Vascular endothelial growth factor-D transgenic mice show enhanced blood capillary density, improved postischemic muscle regeneration, and increased susceptibility to tumor formation." 12/01/2012 - "In this study, we developed an anti-VEGF-D monoclonal antibody, cVE199, and investigated its in vitro properties, in vivo effects against tumors and possible target indications to evaluate its potential as a therapeutic antibody. " 01/01/2015 - "In tumor budding regions VEGF-D-induced receptor activation by autophosphorylation at Tyr1214 seems to be a possible initial event of the VEGFR-2-mediated signaling pathway, but without effect on metastatic behaviour. " 12/01/2014 - "Cancer cell proliferation, lymphangiogenesis, and expression levels of VEGF-D, COX-2, and MMP-2 played important roles in these HO-1-related effects. "
3.	Breast Neoplasms (Breast Cancer) 02/01/2003 - "VEGF-D may be useful in the treatment of breast cancer as a decision-making biomarker for aggressive treatment after operation." 03/01/2005 - "These findings suggest that VEGF-D functions both as an autocrine growth factor and a stimulator of angiogenesis in breast cancer." 03/01/2005 - "VEGF-D and HIF-1alpha in breast cancer." 02/01/2003 - "Whether VEGF-D expression plays prognostic role in breast cancer was also investigated. " 02/01/2003 - "VEGF-D expression is associated with lymph node metastasis and may be a novel prognostic factor in breast cancer. "
4.	Stomach Neoplasms (Stomach Cancer) 01/01/2014 - "STAT3 regulation the expression of VEGF-D in HGC-27 gastric cancer cell." 10/01/2013 - "VEGF-D is the only marker that can be regarded as an unfavorable prognostic indicator for patients with advanced gastric cancer." 10/01/2012 - "VEGF-D is an unfavorable indicator of OS (HR = 1.68, 95 % CI: 1.02-2.34) and DFS (HR = 1.88, 95 % CI: 1.07-2.70) in patients with gastric cancer. " 05/01/2011 - "VEGF-D correlates with metastatic disease in gastric cancer patients undergoing surgery." 08/01/2008 - "VEGF-D expression was observed in 62.5% of the gastric cancers and in 9.6% of the non-neoplastic gastric tissue. "
5.	Lymphangioleiomyomatosis (Lymphangiomyomatosis) 11/01/2015 - "Correlation of serum vascular endothelial growth factor-D concentration with clinical presentation and course of lymphangioleiomyomatosis." 08/01/2013 - "Serum VEGF-D is a biologically plausible and useful biomarker in lymphangioleiomyomatosis that correlates with disease severity and treatment response. " 09/01/2010 - "Serum vascular endothelial growth factor-D prospectively distinguishes lymphangioleiomyomatosis from other diseases." 05/01/2009 - "Serum vascular endothelial growth factor-D levels in patients with lymphangioleiomyomatosis reflect lymphatic involvement." 01/10/2008 - "Diagnostic potential of serum VEGF-D for lymphangioleiomyomatosis."

Related Drugs and Biologics

1.	Vascular Endothelial Growth Factor C
2.	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
3.	Vascular Endothelial Growth Factor Receptor-3 (Flt 4)
4.	Sirolimus (Rapamycin)
5.	lipoarabinomannan (LAM)
6.	platelet-derived growth factor A
7.	Messenger RNA (mRNA)
8.	Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)
9.	Vascular Endothelial Growth Factor D
10.	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)

Related Therapies and Procedures

1.	Heterologous Transplantation (Xenotransplantation)
2.	Drug Therapy (Chemotherapy)
3.	Therapeutics
4.	Gastrectomy
5.	Intravitreal Injections